Skinvisible, Inc. (SKVI)
| Market Cap | 1.62M |
| Revenue (ttm) | 20.00K |
| Net Income (ttm) | -1.06M |
| Shares Out | 5.40M |
| EPS (ttm) | -0.20 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Average Volume | 2,203 |
| Open | 0.300 |
| Previous Close | 0.300 |
| Day's Range | 0.300 - 0.300 |
| 52-Week Range | 0.081 - 0.900 |
| Beta | 1.81 |
| RSI | 48.48 |
| Earnings Date | Apr 14, 2026 |
About Skinvisible
Skinvisible, Inc. focuses on the development, manufacture, and sale of topical, transdermal, and mucosal polymer-based delivery system technologies and formulations for use in pharmaceutical, over-the-counter, personal skincare, and cosmetic arenas. Its non-dermatological formulations offer solutions for women’s health, pain management, and other markets. The company’s flagship product includes Invisicare, a patented polymer delivery system technology that enhances the delivery of active ingredients for topically applied skin care products. It ... [Read more]
Financial Performance
In 2025, Skinvisible's revenue was $20,000, a change of 0.00% compared to the previous year's $20,000. Losses were -$1.06 million, 88.1% more than in 2024.
Financial StatementsNews
Ovation Science and Skinvisible Pharmaceuticals Enhance Their Strategic Partnership in the Obesity Market with Innovative Cannabinoid Delivery Technology with New Developments and Patent Protection
VANCOUVER, BC AND LAS VEGAS, NV / ACCESS Newswire / September 18, 2025 / Ovation Science Inc. (CSE:OVAT)(OTC:OVATF) ("Ovation" or the "Company"), today announced an enhanced strategic partnership with...
Skinvisible Reports Licensee Success in Netherton Syndrome Clinical Studies
Skinvisible Pharmaceuticals, Inc. ("Skinvisible" or "the Company"), (OTCQB:SKVI), an innovative topical and transdermal pharmaceutical research and development company, with proprietary Invisicare® dr...
Skinvisible Announces Article Highlighting Its Proprietary Transdermal Obesity Formulation Development
Drug Development & Delivery Publishes Overview of Obesity Formulation Development Results Demonstrating Significant Transdermal Penetration Using Invisicare Technology LAS VEGAS, NV / ACCESSWIRE / Oct...
Promising Data on Transdermal Obesity Formulations Announced by Skinvisible
Results Demonstrate Significant Transdermal Performance of GLP-1 Receptor Agonists and CB-1 Receptor Antagonists Using Invisicare Technology LAS VEGAS, NV / ACCESSWIRE / July 11, 2024 / Skinvisible Ph...
Skinvisible Expands Obesity Patent Application for Transdermal Delivery
Innovative Delivery System Shows Promise for GLP-1 Agonists, CB-1 Antagonists, and SGLT-2 Inhibitors LAS VEGAS, NV / ACCESSWIRE / June 24, 2024 / Skinvisible Pharmaceuticals, Inc. (OTCQB:SKVI), an inn...
Skinvisible Announces Significant Progress in Licensee's Clinical Trials for Invisicare Formulation Targeting Nethertons Syndrome
LAS VEGAS, NV / ACCESSWIRE / February 14, 2024 / Skinvisible, Inc. ("Skinvisible") (OTCQB:SKVI) is excited to share a promising update on the ongoing clinical trials conducted by its licensee, Quoin P...
Skinvisible Announces First Invisicare Delivery Technology Product to Receive U.S. FDA Acceptance of Investigational New Drug
LAS VEGAS, NV / ACCESSWIRE / June 6, 2022 / Skinvisible, Inc. ("Skinvisible") (OTCQB:SKVI), is pleased to announce that its licensee Quoin Pharmaceuticals, Inc. ("Quoin") (NASDAQ:QNRX), has received U...